Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzylguanidine polyethylene glycol triazole tetraiodothyroacetic acid - NanoPharmaceuticals

Next Previous
Drug Profile

Benzylguanidine polyethylene glycol triazole tetraiodothyroacetic acid - NanoPharmaceuticals

Alternative Names: BG-P-TAT; NP-855

Latest Information Update: 03 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoPharmaceuticals
  • Class Antineoplastics; Antithyroids; Guanidines; Laxatives; Macromolecular substances; Polyethylene glycols; Triazoles
  • Mechanism of Action Integrin alphaVbeta3 antagonists; Norepinephrine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroblastoma; Neuroendocrine tumours

Most Recent Events

  • 03 Oct 2025 Benzylguanidine polyethylene glycol triazole tetraiodothyroacetic acid is still in preclinical development for Neuroblastoma in USA
  • 03 Oct 2025 Benzylguanidine polyethylene glycol triazole tetraiodothyroacetic acid is still in preclinical development for Neuroendocrine tumours in USA
  • 28 Aug 2024 No recent reports of development identified for preclinical development in Neuroblastoma in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top